Anti-Mouse CD19 – PerCP

Pricing & Details

Product No.C2108
Clone
1D3
Protein
CD19
Formats AvailableView All
Product Type
Monoclonal Antibody
Isotype
Rat
IgG2a
Applications
FC
Prod No.
Size
Price
Avail.
Qty
Add to cart
C2108-Custom
Custom
In stock
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Mouse
Host Species
Rat
Immunogen
Fusion of NS-1 Myeloma cells with spleen cells
Product Concentration
0.2 mg/ml
Formulation
This PerCP conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This PerCP conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this 1D3 antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Reported Applications For Relevant Conjugates ?
B
IP
For specific conjugates of this clone, review literature for suggested application details.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone 1D3 recognizes an epitope on mouse CD19.
Antigen Distribution
CD19 is expressed in the majority of Pro-B cells to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19.
Background
CD19 is a 95 kD transmembrane glycoprotein and member of the Ig superfamily. The antigen serves as an adaptor protein; drawing cytoplasmic signaling proteins to the membrane. It works via the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Because of its presence on all B cells, CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for the immunotherapy of lymphoproliferative disorders. Emerging studies indicate that CD19 plays an active role in fueling the growth of these cancers, most notably by stabilizing the concentrations of the MYC oncoprotein, making CD19 an attractive therapeutic target with respect to its downstream signaling.

Antigen Details

Protein
Ligand/Receptor
CD21, CD81, Leu-13.
PubMed
NCBI Gene Bank ID
Research Area
Immunology
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.